Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment ...

A patient with breast cancer was able to avoid unnecessary mastectomy through the use of a virtual reality simulation, ...

Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...

Sevabertinib demonstrated robust, durable responses and manageable safety in both treatment-naïve and pretreated patients with HER2-mutant advanced NSCLC. The combination of sacituzumab with ...

On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...

Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...

Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...

A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...

Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...

BCMA-targeting ADC belantamab mafodotin was approved for use in patients with relapsed/refractory multiple myeloma after 2 or more lines of treatment. Belantamab mafodotin-blmf (Blenrep) has been ...

Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC. The addition of lenvatinib (Lenvima) to ...

Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC. The combination of buparlisib and paclitaxel did not show an ...